Linatab M ER 2.5 mg+1000 mg (Tablet (Extended Release))

Unit Price: ৳ 16.00 (3 x 6: ৳ 288.00)

Strip Price: ৳ 96.00

Medicine Details

Category	Details
Generic	Linagliptin metformin hydrochloride
Company	Incepta pharmaceuticals ltd
Also available as	Linatab m 25 mg tablet Linatab m 25 mg tablet Linatab m 25 mg tablet Linatab m er 5 mg tablet

Indications

Improves glycemic control in adults with type 2 diabetes mellitus
Adjunct to diet and exercise

Pharmacology

Inhibits DPP-4 enzyme
Increases active incretin hormones
Stimulates insulin release
Decreases glucagon secretion
Lowers basal and postprandial plasma glucose
Improves insulin sensitivity
Decreases hepatic glucose production
Decreases intestinal absorption of glucose

Dosage & Administration

Individualized dosage based on effectiveness and tolerability
Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals
Gradual dose escalation to reduce gastrointestinal side effects
Different doses for patients currently treated with or without Metformin Hydrochloride
Extended-release tablet options

Interaction

Interaction with cationic drugs
Potential drug interaction with carbonic anhydrase inhibitors
Inducers of P-glycoprotein and CYP3A4 enzymes
Drugs affecting glycemic control

Contraindications

Not for patients with renal impairment
Contraindicated in acute or chronic metabolic acidosis
Hypersensitivity to Linagliptin or Metformin Hydrochloride

Side Effects

Nasopharyngitis
Diarrhea
Hypoglycemia, especially with sulfonylureas

Pregnancy & Lactation

No adequate and well-controlled studies in pregnant women
Use during pregnancy only if clearly needed
Caution during lactation

Precautions & Warnings

Discontinue in case of lactic acidosis or suspected pancreatitis
Monitor Vitamin B12 levels
Symptoms and precautions for lactic acidosis
Instructions for alcohol, other medicines, counseling, travel, and emergencies
Risk of hypoglycemia

Overdose Effects

Usual supportive measures for overdose
Metformin Hydrochloride is dialyzable
No dose-related adverse drug reactions with Linagliptin
Reported hypoglycemia and lactic acidosis in overdose cases

Therapeutic Class

Combination Oral hypoglycemic preparations

Storage Conditions

Store below 30°C
Protected from light & moisture
Keep out of the reach of children

Related Brands